We are:

  • A Biotechnology Company Specializing in Human Vaccines
  • Creating, Developing, Manufacturing & Testing Innovative AIDS Vaccines
  • Conducting Multiple Site Phase 2 Human Clinical Vaccine Trial

Our AIDS Vaccines:

  • Are Designed for Predominant AIDS Virus Subtypes
  • Use DNA & Viral Vector Technologies
  • Satisfactorily Completed Phase 1 Human Clinical Trial Testing
  • Have Been Proven Safe & Have Demonstrated Ability To Stimulate Immune Responses

Key Market Factors:

  • Vaccines Are The Most Cost Effective Way to Combat Infectious Disease
  • Large Global AIDS Vaccine Market Is Estimated To Be More Than $4 Billion
  • Customer Base Includes All Ages, Genders, Races, Nationalities, Geographical Regions

09 Jan 2012

CEO Update Letter to Shareholders

Read full story (pdf) »

04 Jan 2012

GeoVax Announces Private Offering

Read full story (pdf) »

13 Dec 2011

First Patient Inoculated in Therapeutic Trial

Read full story (pdf) »

10 Nov 2011

Nine Month Financials Announced

Read full story (pdf) »

Clinical Trial Information »

Company Fact Sheet (pdf) »